Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.39 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 3/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.38 |
| ▸ | CTSK | P43235 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5637527 | 0.84 | CTSS (0.48) | PKMKMT2ALMNACYP1A2CYP3A4 | |
| SCHEMBL5637489 | 0.84 | CTSS (0.48) | PKMKMT2ALMNACYP1A2CYP3A4 | |
| SCHEMBL6405777 | 0.80 | PKM (0.49) | PKMKMT2ALMNAALDH1A1CYP1A2 | |
| SCHEMBL6407736 | 0.80 | PKM (0.49) | PKMKMT2ALMNAALDH1A1CYP1A2 | |
| SCHEMBL6601981 | 0.80 | PKM (0.56) | PKMKMT2ALMNACYP1A2CYP3A4 | |
| SCHEMBL14260246 | 0.77 | CYP3A4 (0.49) | PKMKMT2ACYP3A4CTSK | |
| SCHEMBL4904781 | 0.71 | CTSS (0.44) | PKMKMT2ACYP3A4NAMPTCTSK | |
| SCHEMBL4904759 | 0.71 | CTSS (0.44) | PKMKMT2ACYP3A4NAMPTCTSK | |
| SCHEMBL8369521 | 0.71 | CYP3A4 (0.52) | PKMKMT2ACYP3A4NAMPTCTSK | |
| SCHEMBL6648989 | 0.70 | PKM (0.49) | PKMKMT2ALMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CATALANO JOHN G | 2008-03-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080058333-A1 | CYCLOALKYL KETOAMIDES DERIVATIVES USEFUL AS CATHEPSIN K INHIBITORS | CTSK, CTSS, CTSE | PKM 737/4885KMT2A 1064/4885LMNA 2025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.